Edition:
United States

Catalyst Pharmaceuticals Inc (CPRX.O)

CPRX.O on Consolidated Issue listed on NASDAQ Capital Market

1.15USD
17 Feb 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$1.15
Open
--
Day's High
--
Day's Low
--
Volume
11,016
Avg. Vol
584,613
52-wk High
$1.58
52-wk Low
$0.51

CPRX.O

Chart for CPRX.O

About

Catalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115. The Company's... (more)

Overall

Beta: 2.32
Market Cap(Mil.): $95.42
Shares Outstanding(Mil.): 82.97
Dividend: --
Yield (%): --

Financials

  CPRX.O Industry Sector
P/E (TTM): -- 47.00 29.32
EPS (TTM): -0.24 -- --
ROI: -37.39 -4.07 13.03
ROE: -38.10 4.71 14.17

BRIEF-Catalyst Pharmaceuticals announces Q3 2016 financial results

* Catalyst Pharmaceuticals-continues to believe currently available resources will be sufficient to complete development of Firdapse

Nov 09 2016

BRIEF-Catalyst Pharmaceuticals gets FDA special protocol assessment for phase 3 trial of lems treatment

* Says intends to conduct its second phase 3 trial (designated as lms-003) at two clinical trial sites

Oct 31 2016

BRIEF-Catalyst Pharmaceuticals' board entered into amendment no. 1 to rights agreement

* On September 19, 2016, board unanimously approved, and entered into amendment no. 1 to rights agreement - SEC filing

Sep 20 2016

BRIEF-Catalyst Pharmaceuticals announces FDA orphan drug designation of Firdapse

* Catalyst Pharmaceuticals announces FDA orphan drug designation of Firdapse for the treatment of Myasthenia Gravis

Sep 02 2016

More From Around the Web

Earnings vs. Estimates